Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Viridian Therapeutics Inc (NQ: VRDN ) 22.84 +0.56 (+2.51%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Viridian Therapeutics Inc < Previous 1 2 Next > Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock September 11, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock September 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease September 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 September 09, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 05, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results August 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 07, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) July 25, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease June 11, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences May 31, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Participate in Upcoming May Investor Conferences May 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results May 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 April 29, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference March 05, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer February 16, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock January 17, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock January 17, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference January 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease December 18, 2023 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference November 08, 2023 From Viridian Therapeutics, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
